Startup biotechnology company Symmune Therapeutics LLC has raised $125,000 from five investors, according to a filing Thursday with the Securities and Exchange Commission.

The Durham-based company raised the money in the form of debt, options and warrants, according to the filing.

The company said that the proceeds will be used for working capital, which may include compensation to executive officers.

Symmune Therapeutics focuses on the treatment and prevention of pulmonary infections and pulmonary diseases by modulating the immune system to fight infections and reduce inflammation.

Jesse Keicher is the president and founder of the company.

Keicher holds a bachelor’s degree in biochemistry and a master’s degree in chemistry from the University of Oregon. He has over 20 years of pharmaceutical experience at both small biotech and large pharmaceutical companies and is an expert in nonclinical drug development.

At GlaxoSmithKline, he was in charge of the creation and implementation of novel disease treatment strategies including immunomodulatory programs for difficult to treat respiratory tract infections.

He has experience in both building and leading large cross-disciplinary teams consisting of multiple internal and external academic and government collaborators.

Keicher has 20 filed and 13 issued U.S. patents.

Companies similar to Symmune Therapeutics, which rely on a Reg D exemption, aren’t required to register securities offerings with the SEC, but instead they must file a Form D electronically with the SEC after they sell the securities.